Related Experiment Video
Updated: May 25, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Unveiling the effects of GSK126 on osteosarcoma cells implications for apoptosis, autophagy, and cellular migration
Xifeng Xiong1, Yulin Liu2,3, Yanli Du2,4
1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Abstract:
Osteosarcoma, a malignant bone tumor, faces significant treatment challenges. Enhancer of zeste homolog 2 (EZH2) shows aberrant expression in various tumors including osteosarcoma, which is identified as a potential therapeutic target. The anti-cancer efficacy of EZH2 inhibitor GSK126 has attracted attention, yet its impact on osteosarcoma cells was not fully understood. The study investigated the effects of GSK126 on osteosarcoma cells, particularly in apoptosis, autophagy, and cell motility. Our findings revealed that GSK126 induced apoptosis and autophagy, evidenced by increased markers like cleaved caspase-3 and LC3-II, and decreased cellular migration, through downregulation of the Fuse Binding Protein 1 (FBP1)/C-Myc axis. These findings suggest GSK126 as a promising therapeutic against osteosarcoma, offering a dual action of promoting cell death and hindering migration.
Insights
The EZH2 inhibitor GSK126 shows promise for osteosarcoma treatment. It effectively induces apoptosis and autophagy while reducing cell migration by targeting the FBP1/C-Myc pathway.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma is a challenging bone cancer with limited therapeutic options.
- Aberrant Enhancer of zeste homolog 2 (EZH2) expression is implicated in osteosarcoma progression.
- EZH2 inhibitors represent a potential therapeutic strategy for osteosarcoma.
Purpose of the Study:
- To investigate the effects of the EZH2 inhibitor GSK126 on osteosarcoma cells.
- To evaluate GSK126's impact on apoptosis, autophagy, and cell motility.
- To elucidate the molecular mechanisms underlying GSK126's anti-cancer activity in osteosarcoma.
Main Methods:
- Treatment of osteosarcoma cells with GSK126.
- Assessment of apoptosis using markers like cleaved caspase-3.
- Evaluation of autophagy via LC3-II levels.
- Analysis of cell migration.
- Investigation of the Fuse Binding Protein 1 (FBP1)/C-Myc signaling pathway.
Main Results:
- GSK126 treatment significantly induced apoptosis and autophagy in osteosarcoma cells.
- Increased levels of cleaved caspase-3 and LC3-II were observed.
- GSK126 effectively reduced osteosarcoma cell migration.
- These effects were associated with the downregulation of the FBP1/C-Myc axis.
Conclusions:
- GSK126 demonstrates dual therapeutic potential against osteosarcoma by promoting cell death and inhibiting migration.
- Targeting EZH2 with GSK126 offers a promising strategy for osteosarcoma treatment.
- The FBP1/C-Myc axis is a key mediator of GSK126's effects in osteosarcoma.
